Construction officially commenced at the DNE Qingpu Life Science Industry Park on Wednesday.

With a total construction area of 212,300 square meters, the project will serve as a key hub for the gathering of biopharmaceuticals and high-end medical device manufacturing upon completion.

The life science park is invested and constructed by a subsidiary of the DNE Group, a leading new economy infrastructure developer and operator in China, managing over 130 parks. Its business sectors include smart logistics and cold chain, intelligent manufacturing, biopharmaceuticals and urban renewal.

After completion, the DNE park will focus on biopharmaceuticals and high-end medical device manufacturing, providing a comprehensive R&D testing, pilot production, biopharmaceuticals and high-end medical device production chain to create a top-notch biopharmaceutical production smart manufacturing base integrating functions such as "R&D + manufacturing + services."

In recent years, the Qingpu Industrial Park, where the DNE park is located, has accelerated the biopharmaceutical industry cluster development, currently attracting a group of biopharmaceutical companies, such as Baolong Pharmaceutical and Serum Bio-technology, and a group of medical device companies including Chenguang Medical Technologies and Kinetic.